Effects of exogenous cholecystokinin octapeptide on acquisition of naloxone precipitated withdrawal induced conditioned place aversion in rats

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Yu, Hailei ^a   Wen, Di ^a   Ma, Chunling ^a   Meng, Yanxin ^a   Li, Shujin ^a   Ni, Zhiyu ^a   Cong, Bin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; MORPHINE; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NALOXONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVERSION; CONDITIONED PLACE AVERSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; MALE; MICROINJECTION; MORPHINE ADDICTION; NONHUMAN; PLACE PREFERENCE; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; WITHDRAWAL SYNDROME;

ANIMALS; CONDITIONING (PSYCHOLOGY); DEVAZEPIDE; MALE; MORPHINE DEPENDENCE; NALOXONE; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; SPATIAL BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME;

RATTUS;

EID: 84864400362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041860     Document Type: Article

References (53)

1. Carlezon WA Jr,((2003)) Place conditioning to study drug reward and aversion. Methods Mol Med 84:: 243--249.
2. Moran TH, Schwartz GJ,((1994)) Neurobiology of cholecystokinin. Crit Rev Neurobiol 9 (1)():: 1--28.
3. Faris PL, Komisaruk BR, Watkins LR, Mayer DJ,((1983)) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:: 310--312.
4. Pommier B, Beslot F, Simon A, Pophillat M, Matsui T, et al.((2002)) Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. J Neurosci 22 (5)():: 2005--2011.
5. Runkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, et al.((2003)) Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behav Brain Res 144 (1-2):: 125--135.
6. Hebb AL, Poulin JF, Roach SP, Zacharko RM, Drolet G,((2005)) Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry 29 (8)():: 1225--1238.
7. Gospic K, Gunnarsson T, Fransson P, Ingvar M, Lindefors N, et al.((2008)) Emotional perception modulated by an opioid and a cholecystokinin agonist. Psychopharmacology (Berl) 197 (2)():: 295--307.
8. Tanganelli S, Fuxe K, Antonelli T, O'Connor WT, Ferraro L,((2001)) Cholecystokinin/dopamine/GABA interactions in the nucleus accumbens: biochemical and functional correlates. Peptides 22 (8)():: 1229--1234.
9. Koks S, Volke V, Veraksits A, Runkorg K, Sillat T, et al.((2001)) Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl) 158 (2)():: 198--204.
10. Koks S, Abramov U, Veraksits A, Bourin M, Matsui T, et al.((2003)) CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides 37 (1)():: 25--29.
11. Dauge V, Lena I,((1998)) CCK in anxiety and cognitive processes. Neurosci Biobehav Rev 22 (6)():: 815--825.
12. Hamilton ME, Redondo JL, Freeman AS,((2000)) Overflow of dopamine and cholecystokinin in rat nucleus accumbens in response to acute drug administration. Synapse 38 (3)():: 238--242.
13. Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, et al.((1992)) Opioid control of the in vitro release of cholecystokinin-like material from the rat substantia nigra. J Neurochem 58 (3)():: 916--922.
14. Becker C, Pohl M, Thiebot MH, Collin E, Hamon M, et al.((2000)) Delta-opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin- like material by subchronic morphine in rats. Neuropharmacology 39 (2)():: 161--171.
15. Mitchell JM, Bergren LJ, Chen KS, Fields HL,((2006)) Cholecystokinin is necessary for the expression of morphine conditioned place preference. Pharmacol Biochem Behav 85:: 787--795.
16. Lu L, Zhang B, Liu ZY, Zhang ZY,((2002)) Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats. Brain Res 954 (1)():: 132--140.
17. Lu L, Huang M, Ma L, Li J,((2001)) Different role of cholecystokinin (CCK)-A and CCK-B receptors in relapse to morphine dependence in rats. Behav Brain Res 120 (1)():: 105--110.
18. Valverde O, Karsak M, Zimmer A,((2005)) Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 168:: 117--145.
19. Wen D, Cong B, Ma C, Yang S, Yu H, et al.((2012)) The effects of exogenous CCK-8 on the acquisition and expression of morphine-induced CPP. Neurosci Lett 510 (1)():: 24--28.
20. Rezayat M, Azizi N, Zarrindast MR,((1997)) On the mechanism(s) of cholecystokinin (CCK): receptor stimulation attenuates morphine dependence in mice. Pharmacol Toxicol 81 (3)():: 124--129.
21. Wank SA,((1995)) Cholecystokinin receptors. Am J Physiol 269 (5 Pt 1)():: G628--646.
22. Mannisto PT, Lang A, Harro J, Peuranen E, Bradwejn J, et al.((1994)) Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol 349 (5)():: 478--484.
23. Lena I, Simon H, Roques BP, Dauge V,((1999)) Opposing effects of two CCK(B) agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat. Neuropharmacology 38 (4)():: 543--553.
24. Zarbin MA, Wamsley JK, Innis RB, Kuhar MJ,((1981)) Cholecystokinin receptors: presence and axonal flow in the rat vagus nerve. Life Sci 29 (7)():: 697--705.
25. Li Y, Liu X, Chen H, Deng H, Xiang X, et al.((2007)) Development, extinction and reinstatement of morphine withdrawal-induced conditioned place aversion in rats. Addict Biol 12 (3-4)():: 470--477.
26. Wen D, Ma CL, Cong B, Zhang YJ, Yang SC, et al.((2011)) Effects of CCK-8 and its receptor antagonists given intracerebroventricularly on withdrawal symptom of morphine dependent rats. Chin Pharmacol Bull 27 (10)():: 1368--1373.
27. Lu L, Huang M, Liu Z, Ma L,((2000)) Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats. Neuroreport 11 (4)():: 829--832.
28. Itoh S, Katsuura G, Maeda Y,((1982)) Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol 80 (4)():: 421--425.
29. Yan YX, Hu WL, Cong B, Ma CL, Ni ZY, et al.((2007)) Expressions of μ opioid receptor and CCK receptor in rat primary hippocampal neurons and effect of chronic morphine exposure on them. J Fourth MilMed Univ 28 (13)():: 1214--1217.
30. Wang XJ, Fan SG, Ren MF, Han JS,((1989)) Cholecystokinin-8 suppressed 3H-etorphine binding to rat brain opiate receptors. Life Sci 45 (2)():: 117--123.
31. Wang XJ, Han JS,((1990)) Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors. J Neurochem 55 (4)():: 1379--1382.
32. Noble F, Roques BP,((2003)) The role of CCK2 receptors in the homeostasis of the opioid system. Drugs Today (Barc) 39 (11)():: 897--908.
33. Runkorg K, Orav L, Koks S, Matsui T, Volke V, et al.((2012)) Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner. Behav Brain Res 2012 226 (1)():: 335--339.
34. Dauge V, Sebret A, Beslot F, Matsui T, Roques BP,((2001)) Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology 25 (5)():: 690--698.
35. DeSantana JM, da Silva LF, Sluka KA,((2010)) Cholecystokinin receptors mediate tolerance to the analgesic effect of TENS in arthritic rats. Pain 148 (1)():: 84--93.
36. Huang C, Hu ZP, Jiang SZ, Li HT, Han JS, Wan Y,((2007)) CCK(B) receptor antagonist L365,260 potentiates the efficacy to and reverses chronic tolerance to electroacupuncture-induced analgesia in mice. Brain Res Bull 71 (5)():: 447--451.
37. Crespi F,((1998)) The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp Clin Pharmacol 20 (8)():: 679--697.
38. Zhang Z, Schulteis G,((2008)) Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze. Pharmacol Biochem Behav 89 (3)():: 392--403.
39. Rothwell PE, Thomas MJ, Gewirtz JC,((2009)) Distinct profiles of anxiety and dysphoria during spontaneous withdrawal from acute morphine exposure. Neuropsychopharmacology 34 (10)():: 2285--2295.
40. Koob GF,((2012)) Animal models of psychiatric disorders. Handb Clin Neurol 106:: 137--166.
41. Hernandez-Gomez AM, Aguilar-Roblero R, Perez de la Mora M,((2002)) Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids 23 (1-3): 283--290.
42. Ma KT, Si JQ, Zhang ZQ, Zhao L, Fan P, et al.((2006)) Modulatory effect of CCK-8S on GABA-induced depolarization from rat dorsal root ganglion. Brain Res 1121 (1)():: 66--75.
43. Perez de la Mora M, Hernandez-Gomez AM, Arizmendi-Garcia Y, Jacobsen KX, Lara-Garcia D, et al.((2007)) Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [3H]GABA release. Eur J Neurosci 26 (12)():: 3614--3630.
44. Koks S, Soosaar A, Voikar V, Bourin M, Vasar E,((1999)) BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 33 (1)():: 63--69.
45. Heinricher MM, Neubert MJ,((2004)) Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 92 (4)():: 1982--1989.
46. Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L, Hughes J,((1991)) Functional role of brain CCK receptors. Neuropeptides 19 Suppl:: 45--56.
47. Mercer LD, Beart PM,((1997)) Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokininA receptor. Neurosci Lett 225 (2)():: 97--100.
48. Cohen H, Kaplan Z, Matar MA, Buriakovsky I, Bourin M, et al.((2004)) Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats. Depress Anxiety 20 (3)():: 139--152.
49. Lo CM, Samuelson LC, Chambers JB, King A, Heiman J, et al.((2008)) Characterization of mice lacking the gene for cholecystokinin. Am J Physiol Regul Integr Comp Physiol 294 (3)():: R803--810.
50. Hadjiivanova C, Belcheva S, Belcheva I,((2003)) Cholecystokinin and learning and memory processes. Acta Physiol Pharmacol Bulg 27 (2-3)():: 83--88.
51. Miserendino MJ, Sananes CB, Melia KR, Davis M,((1990)) Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345 (6277)():: 716--718.
52. Balschun D, Reymann KG,((1994)) Cholecystokinin (CCK-8S) prolongs 'unsaturated' theta-pulse induced long-term potentiation in rat hippocampal CA1 in vitro. Neuropeptides 26 (6)():: 421--427.
53. Nomoto S, Miyake M, Ohta M, Funakoshi A, Miyasaka K,((1999)) Impaired learning and memory in OLETF rats without cholecystokinin (CCK)-A receptor. Physiol Behav 1999 66 (5)():: 869--872.